A NEW ERA OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION IN CHOLANGIOCARCINOMA

被引：2
|
作者：
Lamarca, A. [1 ,2 ]
Moreno, V. [3 ]
Gambardella, V. [4 ,5 ]
Cervantes, A. [4 ,5 ]
机构：
[1] Fdn Jimenez Diaz Univ Hosp, Oncohealth Inst, Dept Med Oncol, Madrid, Spain
[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England
[3] Fdn Jimenez Diaz Univ Hosp, Dept Med Oncol, START FJD Phase Unit 1, Madrid, Spain
[4] Univ Valencia, Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain
[5] Inst Salud Carlos III, CIBERONC, Madrid, Spain
来源：
ESMO OPEN | 2023年 / 8卷 / 06期
关键词：
METASTATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER; EFFICACY;
D O I：
10.1016/j.esmoop.2023.102032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
    Javle, M.
    Fonkoua, L. A. Kankeu
    Mahipal, A.
    Liao, C-Y.
    Fountzilas, C.
    Li, D.
    Pelster, M. S.
    Goel, S.
    Peng, P.
    Sun, C.
    Wang, H.
    Hennessy, K.
    Fu, X.
    Neo, L.
    Shan, Y.
    Huang, P.
    Wu, D.
    Wu, F.
    Fan, J.
    Piha-Paul, S. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S215 - S216
  • [22] Successful intrahepatic cholangiocarcinoma conversion surgery after administration of fibroblast growth factor receptor inhibitor
    Kaneko, Junichi
    Kiuchi, Ryota
    Takinami, Masaki
    Ohnishi, Ippei
    Ito, Jun
    Jindo, Osamu
    Nishino, Masafumi
    Takahashi, Yurimi
    Yamada, Takanori
    Sakaguchi, Takanori
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (05) : 936 - 942
  • [23] Identification of two new hydrophobic residues on basic fibroblast growth factor important for fibroblast growth factor receptor binding
    Zhu, HY
    Ramnarayan, K
    Menzel, P
    Miao, Y
    Zheng, JH
    Mong, S
    PROTEIN ENGINEERING, 1998, 11 (10): : 937 - 940
  • [24] Fibroblast growth factor receptor 3 inhibition by small interfering RNAs in achondroplasia
    Guzman-Aranguez, Ana
    Legeai-Mallet, Laurence
    Pintor, Jesus
    ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA, 2011, 77 (01): : 4 - 11
  • [25] Specific inhibition of fibroblast growth factor receptor 1 signaling by a DNA aptamer
    Zlinska, Vladimira
    Feketova, Zuzana
    Czyrek, Aleksandra
    Chudzian, Julia
    Zivkovic, Martina Lenarcic
    Ursachi, Vlad-Constantin
    Dudeja, Pooja
    Fafilek, Bohumil
    Rynes, Jan
    Rico-Llanos, Gustavo
    Koudelka, Adolf
    Roy, Tanaya
    Biadun, Martyna
    Raskova, Vendula
    Svozilova, Katerina
    Stroblova, Michaela
    Krzyscik, Mateusz
    Hristova, Kalina
    Krowarsch, Daniel
    Foldynova-Trantirkova, Silvie
    Zakrzewska, Malgorzata
    Trantirek, Lukas
    Krejci, Pavel
    MOLECULAR THERAPY NUCLEIC ACIDS, 2025, 36 (01):
  • [26] mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
    T Scheller
    C Hellerbrand
    C Moser
    K Schmidt
    A Kroemer
    S M Brunner
    H J Schlitt
    E K Geissler
    S A Lang
    British Journal of Cancer, 2015, 112 : 841 - 850
  • [27] Prenatal, but not postnatal, inhibition of fibroblast growth factor receptor signaling causes emphysema
    Hokuto, I
    Perl, AKT
    Whitsett, JA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (01) : 415 - 421
  • [28] The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor
    Morales-Barrera, Rafael
    Suarez, Cristina
    Gonzalez, Macarena
    Valverde, Claudia
    Serra, Ester
    Mateo, Joaquin
    Raventos, Carles
    Maldonado, Xavier
    Morote, Juan
    Carles, Joan
    CANCER TREATMENT REVIEWS, 2020, 86
  • [29] mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
    Scheller, T.
    Hellerbrand, C.
    Moser, C.
    Schmidt, K.
    Kroemer, A.
    Brunner, S. M.
    Schlitt, H. J.
    Geissler, E. K.
    Lang, S. A.
    BRITISH JOURNAL OF CANCER, 2015, 112 (05) : 841 - 850
  • [30] Fibroblast Growth Factor Receptor Inhibitors
    Kumar, Suneel B. V. S.
    Narasu, Lakshmi
    Gundla, Rambabu
    Dayam, Raveendra
    Sarma, J. A. R. P.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (04) : 687 - 701
12345